Watch RNTX. Know when insiders buy.
One email the day a filing lands. Free.
RNTX
Rein Therapeutics, Inc.
0.62
+0.03 +5.01%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
86
PASS · shorts 86
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $53.9MP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$49.8MNET CASH —52W 0.55 – 1.88SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$6.1M | −$6.4M | — | -0.10 | −$8.6M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $0 | — | — | −$5.2M | −$5.8M | — | -0.19 | −$3.4M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$32.7M | −$32M | — | -1.22 | −$3.2M | — | — | May 15 |
| Q3 2025 · Sep 30 | $0 | — | — | −$5.5M | −$5.6M | — | -0.21 | −$3.5M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | $0 | — | — | −$6.9M | −$6.8M | — | -0.28 | −$6.4M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $0 | — | — | −$5.6M | −$5.5M | — | -0.25 | −$6.2M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$42.8M | −$41M | — | -2.20 | −$4.8M | — | — | Mar 26 |
| Q3 2024 · Sep 30 | $0 | — | — | −$6.1M | −$5.8M | — | -0.27 | −$3.8M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | $0 | — | — | −$9M | −$8.9M | — | -0.45 | −$8.4M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | $0 | — | — | −$7.2M | −$7.1M | — | -0.86 | −$5.3M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$7.3M | −$7.3M | — | -1.57 | −$10.4M | — | — | Apr 7 |
| Q3 2023 · Sep 30 | $0 | — | — | −$2M | −$1.8M | — | -0.40 | −$1.6M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$50.6M | −$49.9M | — | -1.96 | −$19.4M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$65.1M | −$62.9M | — | -3.51 | −$22.3M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$16.3M | −$15.7M | — | -3.42 | −$19.8M | — | — | — | — |
| FY2022 · to Dec 31 | $0 | — | −$27.6M | −$27.3M | — | -6.02 | −$24.9M | — | — | — | — |
| FY2021 · to Dec 31 | $0 | — | −$26.6M | −$26.2M | — | -5.89 | −$23.8M | $157K | −$23.9M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$20.5M | −$27.3M | — | -0.61 | −$20.5M | $5K | −$20.5M | — | — |
Every number comes from Rein Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.